BiologicsTop Stories

Kolosis BIO Announces 2021 Results

 • Kolosis bone grafts available in over 270 hospitals and surgical facilities in 46 states
 • Grafts utilized in approximately 6000 fusion procedures during the year
 • Expanded national footprint through ~100 independent distributors
 • Successful launch of Kore Fiber with rapid market adoption and positive early clinical performance. Kore
added to over 30 health system and GPO contracts

SALT LAKE CITY, Utah – March 16, 2022 / OrthoSpineNews / – Kolosis BIO, LLC (Kolosis), a pure-play orthobiologics company and an exclusive partner to MTF Biologics, announced today its 2021 results and 2022 expectations.

2021 saw strong revenue growth primarily driven by the launch of Kore Fiber and by the continued strong performance of the Prime HD DBM tissue-form. Kolosis anticipates doubling its revenue in 2022 as it grows its direct and indirect sales force, expands contractual access for its bone graft portfolio, and provides additional scientific evidence for its technologies.

“We couldn’t be more pleased with the launch of Kore Fiber and the interest in the technology we are seeing from clinicians and sales partners alike,” said Collin Begley, CEO. “Delivering high quality MTF grafts to over 6000 patients during the year is a humbling accomplishment for our team. Looking towards 2022 and beyond, our salesforce expansion trajectory, scientific initiatives, and initial clinical outcomes give us a pathway to deliver continued robust growth.”

Kolosis President, Keegan Begley, added, “Our value proposition in the market is extremely compelling with best-in-class aseptically processed technologies from MTF and rapidly expanding contract access for our bone graft portfolio. I’m pleased with our performance and that we’re delivering a level of responsiveness to our customers that is simply impossible for our big company competitors to match.”

About Kolosis BIO:

Kolosis BIO is a pure-play orthobiologics company dedicated to commercializing Bold Technologies with Relentless Execution. Kolosis exclusively partners with MTF to deliver market-leading bone graft technologies in the orthopedic space. The company represents two MTF bone graft technologies; Kore Fiber, a 100% cortical fiber allograft, and Prime HD, a pre-hydrated DBM. Both grafts offer superior quality through MTF’s proprietary aseptic processing methods which optimally preserve matrix structures and osteoinductive properties. For more information visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research. We provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of life, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists. Our subsidiary, The International Institute for the Advancement of Medicine (IIAM), honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Our subsidiary, Statline, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Our sister organization, The German Institute for Cell and Tissue Transplantation (Deutsches Institute for Zell-und Gewebeersatz – DIZG) expands our reach to patients across the globe. For more information, visit

Maxwell Hunter- Chief Operations Officer
Tel 801-602-0040

Chris J. Stewart

Chris currently serves as President and CEO of Surgio Health. Chris has close to 20 years of healthcare management experience, with an infinity to improve healthcare delivery through the development and implementation of innovative solutions that result in improved efficiencies, reduction of unnecessary financial & clinical variation, and help achieve better patient outcomes. Previously, Chris was assistant vice president and business unit leader for HPG/HCA. He has presented at numerous healthcare forums on topics that include disruptive innovation, physician engagement, shifting reimbursement models, cost per clinical episode and the future of supply chain delivery.

Related Articles

Back to top button